AZ, Lilly pull plug on Alzheimer’s disease trials
Alzheimer’s disease research has taken another hit with the failure of AstraZeneca and Eli Lilly’s experimental BACE inhibitor lanabecestat.
Read More
Tag: lanabecestat
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
